UCL President and Provost, Professor Michael Arthur, visited the Division’s
Stanmore campus earlier this month, to meet staff and students from the
Institute of Orthopaedics and Musculoskeletal Science (IOMS) and the Royal
National Orthopaedic Hospital (RNOH).
Published: Jul 18, 2014 11:39:14 AM
Having recently collaborated with the Science Museum in February this year where she hosted a Nanotechnology workshop at the Science Museum’s Lates event, Melissa Bovis, Research Associate, teamed up with the Museum for a second time this month as part of their Building Bridges scheme. More...
Published: Jul 18, 2014 11:18:05 AM
40,000 men are diagnosed with prostate cancer every year in the UK. There is
much uncertainty about which treatments might be best for these men, so Level I
evidence is often required. Traditionally, Level I evidence comprises a
head-to-head randomised controlled trial (RCT) of a new intervention versus
placebo in which neither the patient nor the doctor knows who is taking what
(‘double-blind’). The treatment allocation is based on chance and the blinding
prevents biases. In surgery, this design is not always ethical or practical.
This means that both doctor and patient have to be made aware of the treatment
received in surgical trials. This causes problems. First, surgeons and patients
often have strong - but sometimes misplaced - ideas of what works, so RCTs are
difficult to recruit to. Second, this often means patients have to seek out
trials, leading to a select group of motivated, commonly more educated and
affluent patients participating in trials. Third, patients who take part in a
trial may not approve of the treatment they have been allocated by chance and
withdraw. These factors have led to the failure of many surgical trials to
accrue. This has been particularly highlighted in localised prostate cancer
RCTs. In fact, 11 RCTs evaluating different interventions in localised prostate
in the last decade have failed to recruit.
Published: Jul 18, 2014 11:06:56 AM
The Division is delighted
to announce that it has been awarded an Athena Swan Bronze Award for its
efforts in supporting and empowering women within the Division.
Published: May 30, 2014 11:40:35 AM
Miss Clare Marx, Consultant Orthopaedic Surgeon and Associate Medical Director at Ipswich Hospital NHS Trust, will be speaking at the Division’s Academic Surgical Meeting in July. More...
Published: May 30, 2014 11:36:17 AM
Dr Kate Ricketts, Lecturer in Cancer Nanotechnology, has been awarded a grant under the Wellcome Trust Institutional Strategic Fund-Investing in Excellent Researchers scheme as principal investigator for the use of nanoparticles as theranostic radiosensitisers. More...
Published: May 30, 2014 11:29:52 AM
Hashim Ahmed, Senior Clinical Lecturer and Honorary Consultant Urological Surgeon, has been awarded £171,000 from Prostate Cancer UK to test the hypothesis that multi-parametric ultrasound has the ability to detect and rule-out clinically significant prostate cancer as an alternative to biopsies. More...
Published: May 30, 2014 11:27:59 AM
This month, the spotlight is on Dr Laurence Lovat, Head of the Research Department of Tissue and Energy and Reader in Gastroenterology and Laser Medicine. More...
Published: May 30, 2014 11:09:38 AM